Enjoy complimentary customisation on priority with our Enterprise License!
HER2-negative breast cancer is a type of breast cancer that is characterized by low levels of HER2 gene expression. The cancers which have detectable hormone receptors are known as HR positive breast cancer, whereas those with HER2-negative have low levels of HER2 proteins. The global market for HER2-negative breast cancer is envisaged to post a strong market growth rate of close to 16% by 2019. Factors like its ability to cater to the unmet needs of the patients are expected to impel growth in this market during the forecast period.
Technavio’s market research analysts have estimated the Americas to dominate this market during the forecast period followed by the EMEA and the APAC regions. In the Americas, the US is estimated to be the highest revenue contributor due to factors like high-unmet medical needs of patients and the expected launch of pipeline products in the next four years.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.